Evaluation of the combination of brentuximab vedotin and chemotherapy in peripheral CD30 + T lymphomas: controlled, randomized, double-blind trial

被引：0
|
作者：
Charlotte, Berthoux
Laure, Farnault
Geoffroy, Venton
机构：
来源：
HEMATOLOGIE | 2019年 / 25卷 / 02期
关键词：
D O I：
10.1684/hma.2019.1459
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [31] Epigenetic Modulation of CD30 Gene Expression in Alemtuzumab Resistant T Cell Malignancy: Rationale and Efficacy of Brentuximab Vedotin
    Hasanali, Zainul
    Sharma, Kamal
    Shimko, Sara
    Stuart, August
    Epner, Elliot M.
    BLOOD, 2012, 120 (21)
  • [32] Phase II trial of Brentuximab vedotin (SGN-35) for CD30+cutaneous T-cell lymphomas and lymphoproliferative disorders
    Duvic, M.
    Tetzlaff, H.
    Gangar, P.
    Clos, A. L.
    Talpur, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S180 - S180
  • [33] Real Life Experience of Brentuximab Vedotin Plus CHP As First-Line Treatment in CD30+Peripheral T-Cell Lymphomas
    Domenech Eva, Domingo
    Sancho, Juan-Manuel
    Gonzalez-Barca, Eva
    Kelleher, Nicholas
    Rodriguez-Luaces, Marta
    Rovira Sole, Jordina
    Verdesoto, Silvia
    Encuentra, Maite
    Blazevic, Damir
    Oliveira, Ana C.
    Escoda, Lourdes
    Ribera, Josep-Maria
    Sureda, Anna
    BLOOD, 2021, 138
  • [34] Combining BeEAM with brentuximab vedotin for high-dose therapy in CD30 positive lymphomas before autologous transplantation - a phase I study
    Rausch, C.
    Bacher, U.
    Rabaglio, M.
    Banz, Y.
    Daskalakis, M.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 14S - 14S
  • [35] Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
    Fanale, Michelle A.
    Horwitz, Steven M.
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Advani, Ranjana H.
    Pro, Barbara
    Chen, Robert W.
    Davies, Andrew
    Illidge, Tim
    Huebner, Dirk
    Kennedy, Dana A.
    Shustov, Andrei R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3137 - +
  • [36] The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
    Iyer, Swaminathan
    Truemper, Lorenz
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana
    Menne, Tobias
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei
    Huettmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Miao, Harry
    Bunn, Veronica
    Fenton, Keenan
    Fanale, Michelle
    Puhlmann, Markus
    Horwitz, Steven
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S411 - S411
  • [37] The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
    Horwitz, Steven M.
    O'Connor, Owen A.
    Pro, Barbara
    Illidge, Tim
    Iyer, Swami P.
    Advani, Ranjana
    Bartlett, Nancy L.
    Christensen, Jacob Haaber
    Morschhauser, Franck
    Domingo-Domenech, Eva
    Rossi, Giuseppe
    Kim, Won Seog
    Feldman, Tatyana A.
    Menne, Tobias
    Belada, David
    Illes, Arpad
    Tobinai, Kensei
    Tsukasaki, Kunihiro
    Yeh, Su-Peng
    Shustov, Andrei R.
    Huttmann, Andreas
    Savage, Kerry J.
    Yuen, Sam
    Zinzani, Pier Luigi
    Miao, Harry
    Bunn, Veronica
    Fenton, Keenan
    Fanale, Michelle A.
    Puhlmann, Markus
    Truemper, Lorenz
    BLOOD, 2020, 136
  • [38] Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data
    Enos, Tyler H.
    Feigenbaum, Lawrence S.
    Wickless, Heather W.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1400 - 1405
  • [39] Intralesional brentuximab vedotin: our experience in the treatment of CD30+primary cutaneous T-cell lymphomas
    Arroyo Andres, J. A.
    Rubio Muniz, C. A.
    Agud De Dios, M. A.
    Falkenhain Lopez, D.
    Mitsunaga, K.
    Sanchez Velazquez, A.
    Postigo Llorente, C.
    Ortiz-Romero, P. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S50 - S51
  • [40] Cost-Effectiveness of brentuximab vedotin with chemotherapy in frontline treatment of CD30-expressing peripheral T-cell lymphoma.
    Feldman, Tatyana
    Zou, Denise
    Rebeira, Mayvis
    Lee, Joseph
    Harris, Mack
    Ma, Wenkang
    Fanale, Michelle A.
    Manley, Thomas John
    Feliciano, Joseph
    Rao, Shangbang
    Kansal, Anuraag
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345